We previously reported that [fam-] trastuzumab deruxtecan enhances antitumor immunity in a mouse model by upregulating MHC class I expression on cancer cells and activation markers on DCs and increasing the prevalence of intra-tumor CD8+ T cells [19]. This evidence concerns the gene CD8A and neoplasm.